Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novo Nordisk A/S : Ontario becomes first province to provide public funding of TRESIBA® for adults with diabetes mellitus

share with twitter share with LinkedIn share with facebook
share via e-mail
09/21/2018 | 02:13pm CET

TRESIBA® is the first insulin added to Health Canada's Register of Innovative Drugs

Manitoba to reimburse Tresiba® following Ontario listing

MISSISSAUGA, ON, Sept. 21, 2018 /CNW/ - Novo Nordisk Canada Inc. announces that Ontario will now reimburse TRESIBA® (insulin degludec injection) FlexTouch® prefilled pen in both 100 units/mL and 200 units/mL doses, as a general benefit for people living with Type 2 and Type 1 diabetes. TRESIBA® is an ultra-long-acting basal insulin, for adults with diabetes mellitus, and will now be reimbursed under the Ontario Drug Benefit program, effective September 27, 2018.1,2

Novo Nordisk Canada Inc. (CNW Group/Novo Nordisk Canada Inc.)

In addition, the Government of Manitoba also announced that it will reimburse TRESIBA® (insulin degludec injection) for both 100 units/mL and 200 units/mL doses under the Manitoba Drug Benefits and Interchangeability Formulary, effective October 18, 2018.3 

"Having the ability to choose which insulin works best for them can have a great impact on how well people with diabetes are able to manage their blood sugar levels," says Dr. Jan Hux, President of Diabetes Canada. "The governments of Ontario and Manitoba have shown leadership by improving access to medications through the addition of a new insulin to their public drug program formularies, and we encourage the rest of Canada to do the same."

The addition of TRESIBA® to the Ontario Drug Benefit program and Manitoba Drug Benefits and Interchangeability Formulary represents an important milestone for people living with diabetes. Following its approval by Health Canada in August 2017, TRESIBA® became the first insulin added to the Register of Innovative Drugs for human use and has obtained its first provincial listing promptly after regulatory approval.

"We applaud the governments of Ontario and Manitoba for taking this important step in making innovative treatments more easily available to those living with diabetes in these provinces," says Dave Prowten, President and CEO, JDRF Canada. "When it comes to treatments that help people better manage their Type 1 diabetes, JDRF continues to support both access and choice."

About Tresiba®
Tresiba® (insulin degludec injection) is a once-daily, ultra-long-acting basal insulin approved in Canada on August 25, 2017 for the once-daily treatment of adults with diabetes mellitus to improve glycemic control.1 Tresiba® provides a duration of action beyond 42 hours with a flat and stable glucose-lowering effect.1,4 It has been shown to provide a lower risk of overall, nocturnal and severe hypoglycemia, and low variability in blood sugar levels versus insulin glargine U100.1,5 Tresiba® received its first regulatory approval in September 2012 and has since been approved in more than 80 countries globally. It is now commercially available in more than 61 countries.

Hypoglycemia is the most common adverse reaction of all insulin preparations, including Tresiba®. The most common side effects found with Tresiba® are hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain.1

About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, hemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,700 people in 77 countries and markets its products in more than 165 countries. For more information, visit novonordisk.ca, Twitter, YouTube.


  1. Novo Nordisk Canada Inc. TRESIBA® Product Monograph. July 17, 2018. http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-novonordisk-ca/OurProducts/PDF/tresiba-product-monograph.pdf. Accessed July 24, 2018.
  2. Ontario Drug Benefit Formulary/Comparative Drug Index. Edition 43. September 20, 2018. http://www.health.gov.on.ca/en/pro/programs/drugs/formulary43/summary_edition43_20180920.pdf. Accessed September 20, 2018.
  3. Bulletin #101. Manitoba Drug Benefits and Interchangeability Formulary Amendments. September 20, 2018. http://www.gov.mb.ca/health/mdbif/docs/bulletins/. Accessed September 20, 2018.
  4. Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014; 53:787-800.
  5. Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Eng J Med. 2017. DOI: 10.1056/NEJMoa1615692.

SOURCE Novo Nordisk Canada Inc.

© Canada Newswire, source Canada Newswire English

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVO NORDISK A/S
12/13NOVO NORDISK A/S : begins R&D tie-up with AI biotech e-Therapeutics
12/12NOVO NORDISK A/S : opens one-stop Diabetes Support Centre in Suntreso Government..
12/11FDA biosimilars policies will bring interchangeable insulin to market
12/11NOVO NORDISK A/S : not engaged in economic activity in Nagorno-Karabakh region
12/11E THERAPEUTICS : Danish drugs giant Novo Nordisk to use e-Therapeutics technolog..
12/11NOVO NORDISK A/S : opens one-stop Diabetes Support Centre in Suntreso Government..
12/10NOVO NORDISK A/S : opens one-stop Diabetes Support Centre in Suntreso Government..
12/10NOVO NORDISK A/S : Disclosure of transaction data
12/10NOVO NORDISK A/S : - Share repurchase programme
12/08NOVO NORDISK A/S : pumps $22m into insulin manufacturing site
More news
Financials (DKK)
Sales 2018 112 B
EBIT 2018 47 774 M
Net income 2018 39 047 M
Finance 2018 15 585 M
Yield 2018 2,63%
P/E ratio 2018 18,92
P/E ratio 2019 18,21
EV / Sales 2018 5,09x
EV / Sales 2019 4,83x
Capitalization 583 B
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 326  DKK
Spread / Average Target 6,9%
EPS Revisions
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S-8.83%88 704
JOHNSON & JOHNSON5.81%396 504
PFIZER21.92%258 506
NOVARTIS6.21%224 691
ROCHE HOLDING LTD.3.12%220 215
MERCK AND COMPANY40.41%205 456